Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred P Lutz

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|April 1, 2010
A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische OnkologieVolker Kaechele, Markus Moehler, Manfred P Lutz, et al.
BMC Cancer|July 11, 2019
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette studyStefan Heinrich, Marc Besselink, Markus Moehler, et al.
Acta Oncologica (Stockholm, Sweden)|August 6, 2021
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial datasetAnnett Maderer, Frederic Fiteni, Erik Tanis, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
British Journal of Cancer|August 24, 2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupThibaud Koessler, Maria Alsina, Dirk Arnold, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2015
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983Erik Tanis, Catherine Julié, Jean-Francois Emile, et al.
Clinical Colorectal Cancer|May 31, 2022
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer groupFrancesco Sclafani, Elisa Fontana, Lucjan Wyrwicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische OnkologieManfred P Lutz, Hansjochen Wilke, D J Theo Wagener, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2025
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysisGiacomo Bregni, Bryan Leurquin, Peggy Giasafaki, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|April 1, 2010
A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische OnkologieVolker Kaechele, Markus Moehler, Manfred P Lutz, et al.
BMC Cancer|July 11, 2019
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette studyStefan Heinrich, Marc Besselink, Markus Moehler, et al.
Acta Oncologica (Stockholm, Sweden)|August 6, 2021
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial datasetAnnett Maderer, Frederic Fiteni, Erik Tanis, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
British Journal of Cancer|August 24, 2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupThibaud Koessler, Maria Alsina, Dirk Arnold, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2015
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983Erik Tanis, Catherine Julié, Jean-Francois Emile, et al.
Clinical Colorectal Cancer|May 31, 2022
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer groupFrancesco Sclafani, Elisa Fontana, Lucjan Wyrwicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische OnkologieManfred P Lutz, Hansjochen Wilke, D J Theo Wagener, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2025
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysisGiacomo Bregni, Bryan Leurquin, Peggy Giasafaki, et al.
Pageof 4